- Program Director, Hematology and Oncology, UH Cleveland Medical Center
- Assistant Professor, CWRU School of Medicine
- Acute Leukemia
- Chronic Leukemia
- Clinical Trials Research
- Hematologic Malignancies
- Myelodysplastic Syndromes
Patient Experience Reviews
4.8 out of 5
Patient Comments (10)
Reviewed On 6/1/2021
Reviewed On 5/1/2021
Dr Tomlinson is an excellent doctor
Reviewed On 4/1/2021
Dr Tomlinson is a great physician
Reviewed On 4/1/2021
The doctor was very attentive, extremely knowledgeable and I am comfortable with his treatment.
Reviewed On 2/1/2021
very good and doctor and nurses were very informative about my illness and what is to expected
Reviewed On 1/1/2021
Found Dr. Tomlinson to be a caring, kind and extremely knowledgeable doctor.
Reviewed On 12/1/2020
Dr. Tomlinson is a very good Dr. and he cares about his patients to make sure they understand.
Reviewed On 11/1/2020
*** Everyone at Seidman from the office staff to the nurses to the doctors and especially Dr. Tomlinson are exceptional. I feel very fortunate to be under his care.
Reviewed On 9/1/2020
*** Dr. Tomlinson and the entire Seidman team are just outstanding. I am very fortunate to be one of his patients and to be getting my treatment at Seidman.
Reviewed On 8/4/2020
Dr. Tomlinson is an excellent Doctor. Any hospital should be honored to have him as a physician practicing at there facility.
- Medical Oncology - American Board of Internal Medicine
- Hematology - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Fellowship | Hematology/Oncology
Hematology/Oncology - University Of California At Davis Comprehensive Cancer Center (2012 - 2015)
Residency | Internal Medicine
Internal Medicine - Uc Davis Medical Center (2009 - 2012)
Case Western Reserve University School Of Medicine (2009)
Case Western Reserve University (2005)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Benjamin Tomlinson did not disclose any Outside Relationships with Industry.